Larimar Therapeutics Reports Q1 Loss, Advances Key Drug Towards June BLA Submission
LRMR has more than doubled off its 52-week low of $1.73 on light trading volume (0.2× avg).
Summary
Larimar Therapeutics reported a Q1 net loss of $29.61 million, which widened slightly, while R&D expenses decreased due to reduced manufacturing and clinical trial costs for nomlabofusp. General and administrative expenses rose as the company prepares for commercialization. Critically, the company reiterated its plan to initiate a rolling Biologics License Application (BLA) submission for nomlabofusp in June 2026, with final modules expected in the second half of the year. This follows an 8-K filed earlier today announcing the same BLA timeline. The company also confirmed a cash runway into the second quarter of 2027, providing financial stability. While the headline focuses on the loss, the overall context of pipeline progression and strong liquidity is key for this clinical-stage biotech. Investors will closely watch for the initiation of the BLA submission in June.
At the time of this announcement, LRMR was trading at $4.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425.9M. The 52-week trading range was $1.73 to $6.42. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.